Skip to Content
Merck
CN
  • Metabolic studies in a patient with severe carnitine palmitoyltransferase type II deficiency.

Metabolic studies in a patient with severe carnitine palmitoyltransferase type II deficiency.

Clinica chimica acta; international journal of clinical chemistry (1998-07-10)
M Fontaine, G Briand, C Largillière, P Degand, P Divry, C Vianey-Saban, B Mousson, J Vamecq
ABSTRACT

Here we report on a patient with severe ("non-classic") carnitine palmitoyltransferase type II (CPT II) deficiency. Hypoglycemia prompted by an infectious episode and associated with non-ketotic dicarboxylic aciduria orientated diagnosis towards beta-oxidation deficiency disorders. Blood carnitine levels revealed a secondary carnitine deficiency that was responsive to oral L-carnitine supplementation. Blood acylcarnitine profiles were abnormal and included acetyl (C2:0), butyryl/isobutyryl (C4:0), isovaleryl/2-methylbutyryl (C5:0), hexanoyl (C6:0), myristoyl (C14:0), palmitoyl (C16:0), hexadecenoyl (C16:1), oleyl (C18:1) and stearoyl (C18:0) carnitine. In urine, excess excretion of dicarboxylylcarnitines, mainly dodecanedioylcarnitine, was noticed. Upon carnitine supplementation, C8 to C12 fatty acylcarnitines, with decanoylcarnitine as well as C10 to C14 dicarboxylylcarnitines being prominent, were observed in urine. Biochemical measurements disclosed a severe reduction of mitochondrial CPT II activity (7% of normal values). Correlations of metabolic findings in the patient and physiological roles of CPT II are briefly discussed.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Isobutyryl-L-carnitine, ≥97.0% (HPLC)